OPKO Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on November 14, 2011, by OPKO Health, Inc. The filing addresses the fiscal year ended December 31, 2010, and specifically updates the presentation of financial data to reflect a significant corporate transaction completed in October 2011.
Key Financial Metrics and Transaction Details
The filing does not provide specific revenue, profit, cash flow, or margin figures for the current period. Instead, it details a material asset sale:
- Transaction: Sale of the ophthalmic instrumentation business to OPTOS, Inc. (a subsidiary of Optos plc).
- Consideration: $17.5 million in cash plus royalties up to $22.5 million on future sales.
- Accounting Treatment: The Instrumentation Business has been reclassified as "discontinued operations" because its cash flows are independent and the Company will not have significant continuing involvement beyond one year.
Material Changes Versus Prior Period
The primary material change is the recasting of consolidated financial statements for the five-year period ended December 31, 2010. This recasting separates the Instrumentation Business results from continuing operations. The filing explicitly states that this is a change in presentation and does not constitute a restatement of previously issued financial statements.
Guidance, Outlook, and Risks
The filing does not contain new forward-looking guidance, management commentary on future performance, or specific risk factors beyond the context of the business sale. It notes that the updated financial data (Exhibit 99.1) does not reflect events occurring after the filing of the 2010 Form 10-K. Investors are directed to read this report in conjunction with the 2010 Form 10-K and subsequent filings for complete disclosures.
Key Facts for Investor Verification
- Verify the exact impact of the $17.5 million cash and potential $22.5 million royalties on the Company's liquidity and future revenue streams.
- Review Exhibit 99.1 to analyze the recasted financial statements showing the Instrumentation Business as discontinued operations.
- Confirm that no other disclosures in the 2010 Form 10-K have been modified or updated by this filing.
- Assess the Company's strategic focus following the divestiture of the ophthalmic instrumentation segment.